| Line Item | 2023-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $21.9M | +290.8% |
| SG&A Expense | $10.6M | +28.0% |
| Operating Income | -$32.5M | -133.8% |
| Net Income | -$31.5M | -126.8% |
| EPS (Basic) | -$1.00 | -25.0% |
| EPS (Diluted) | -$1.00 | -25.0% |
| Line Item | 2023-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $37.1M | -9.7% |
| Current Assets | $38.3M | -7.7% |
| Total Assets | $39.0M | -7.2% |
| Current Liabilities | $3.7M | +15.3% |
| Stockholders' Equity | $35.3M | -9.0% |
| Line Item | 2023-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$28.7M | -250.7% |
| Capital Expenditures | $88K | — |
| Investing Cash Flow | $47K | — |
| Financing Cash Flow | $24.7M | +240.9% |
| Free Cash Flow | -$28.8M | — |